The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Phase II IMpress study: imetelstat in patients with advanced MDS or AML failing HMA-based therapy
In this video, Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, comments on the interim analysis results of the Phase II IMpress study (NCT05583552) evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) failing hypomethylating agent (HMA)-based therapy. The study did not identify any new safety signals, but unfortunately, no remissions were achieved according to protocol-defined endpoints. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen: Consultancy, Research Funding; BMS: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Other: Travel support, Research Funding; MDS Foundation: Membership on an entity’s Board of Directors or advisory committees; Abbvie: Consultancy, Research Funding; Curis: Consultancy, Honoraria, Research Funding; Geron: Consultancy; Janssen: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Novartis: Consultancy, Research Funding.
